Cargando…

Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells

Cell-based therapies using genetically engineered lymphocytes expressing antigen-specific T cell receptors (TCRs) hold promise for the treatment of several types of cancers. Almost all studies using this modality have focused on transfer of TCR from CD8 cytotoxic T lymphocytes (CTLs). The transfer o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Kanako, Shinga, Jun, Yamasaki, Satoru, Kawamura, Masami, Dörrie, Jan, Schaft, Niels, Sato, Yusuke, Iyoda, Tomonori, Fujii, Shin-ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488262/ https://www.ncbi.nlm.nih.gov/pubmed/26121617 http://dx.doi.org/10.1371/journal.pone.0131477

Ejemplares similares

Vaccine Designs Utilizing Invariant NKT-Licensed Antigen-Presenting Cells Provide NKT or T Cell Help for B Cell Responses
por: Fujii, Shin-ichiro, et al.
Publicado: (2018)

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
por: Shimizu, Kanako, et al.
Publicado: (2020)

Augmenting Granzyme B–Expressing NK Cells by Invariant NKT Ligand–Loaded APCs in Patients with Postoperative Early Stage Non–Small Cell Lung Cancer: Results of a Randomized Phase II Study
por: Iyoda, Tomonori, et al.
Publicado: (2023)

Eomes transcription factor is required for the development and differentiation of invariant NKT cells
por: Shimizu, Kanako, et al.
Publicado: (2019)

Invariant NKT cells recognize glycolipids from pathogenic Gram-positive bacteria
por: Kinjo, Yuki, et al.
Publicado: (2011)

Zeb2 regulates differentiation of long-lived effector of invariant natural killer T cells
por: Iyoda, Tomonori, et al.
Publicado: (2023)

Optimal therapeutic strategy using antigen‐containing liposomes selectively delivered to antigen‐presenting cells
por: Iyoda, Tomonori, et al.
Publicado: (2019)

Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells
por: Fujii, Shin-ichiro, et al.
Publicado: (2017)

Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity
por: Fujii, Shin-ichiro, et al.
Publicado: (2022)

Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
por: Iyoda, Tomonori, et al.
Publicado: (2023)

Thymus medulla fosters generation of natural Treg cells, invariant γδ T cells, and invariant NKT cells: What we learn from intrathymic migration
por: Cowan, Jennifer E, et al.
Publicado: (2015)

Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
por: Fujii, Shin‐ichiro, et al.
Publicado: (2022)

Activation of Invariant NKT Cells with Glycolipid Ligand α-Galactosylceramide Ameliorates Glucose-6-Phosphate Isomerase Peptide-Induced Arthritis
por: Horikoshi, Masanobu, et al.
Publicado: (2012)

In vivo dendritic cell targeting cellular vaccine induces CD4(+) Tfh cell-dependent antibody against influenza virus
por: Yamasaki, Satoru, et al.
Publicado: (2016)

Gender‐dependent frequency of unconventional T cells in a healthy adult Caucasian population: A combinational study of invariant NKT cells, γδ T cells, and mucosa‐associated invariant T cells
por: Singh, Parvind, et al.
Publicado: (2022)

A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition
por: Kjer-Nielsen, Lars, et al.
Publicado: (2006)

NKT Cells as an Ideal Anti-Tumor Immunotherapeutic
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)

Intracellular Bacterial Infection and Invariant NKT Cells
por: Emoto, Masashi, et al.
Publicado: (2009)

NKT cell-dependent glycolipid–peptide vaccines with potent anti-tumour activity
por: Anderson, Regan J., et al.
Publicado: (2015)

22511 Glycolipid-loaded nanoparticles harness iNKT cells for tumor immunotherapy
por: Shute, Travis, et al.
Publicado: (2021)

PD-L1 Expression Affects Neoantigen Presentation
por: Okada, Masahiro, et al.
Publicado: (2020)

Invariant NKT cells: Killers and conspirators against cancer
por: Bassiri, Hamid, et al.
Publicado: (2013)

Improved Detection of Cytokines Produced by Invariant NKT Cells
por: Sag, Duygu, et al.
Publicado: (2017)

A Rapid Fluorescence-Based Assay for Classification of iNKT Cell Activating Glycolipids
por: Arora, Pooja, et al.
Publicado: (2011)

First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis
por: Sato, Wakiro, et al.
Publicado: (2023)

Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells
por: Catafal-Tardos, Elisa, et al.
Publicado: (2021)

NFATc1 induction by an intronic enhancer restricts NKT γδ cell formation
por: Giampaolo, Sabrina, et al.
Publicado: (2023)

Tailored design of NKT-stimulatory glycolipids for polarization of immune responses
por: Hung, Jung-Tung, et al.
Publicado: (2017)

Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
por: Hunn, Martin K., et al.
Publicado: (2013)

Activation of Invariant NKT Cells Exacerbates Experimental Visceral Leishmaniasis
por: Stanley, Amanda C., et al.
Publicado: (2008)

Invariant NKT Cells: Regulation and Function during Viral Infection
por: Juno, Jennifer A., et al.
Publicado: (2012)

Invariant NKT Cell Response to Dengue Virus Infection in Human
por: Matangkasombut, Ponpan, et al.
Publicado: (2014)

Invariant NKT Cells as Novel Targets for Immunotherapy in Solid Tumors
por: Pilones, Karsten A., et al.
Publicado: (2012)

Effects of Invariant NKT Cells on Parasite Infections and Hygiene Hypothesis
por: Yang, Jun-Qi, et al.
Publicado: (2016)

Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
por: Wolf, Benjamin J., et al.
Publicado: (2018)

Immune cells and preterm labour: do invariant NKT cells hold the key?
por: Rinaldi, S.F., et al.
Publicado: (2015)

Cross-talk between cd1d-restricted nkt cells and γδ cells in t regulatory cell response
por: Liu, Wei, et al.
Publicado: (2011)

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
por: Harrer, Dennis C., et al.
Publicado: (2017)

Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
por: Shimizu, Kanako, et al.
Publicado: (2007)

The human fetal thymus generates invariant effector γδ T cells
por: Tieppo, Paola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_73oh7ualmka5nafgq9pn5eanc2